PMC

Figure 2. The antibody-dye conjugates were assessed against IgG-IRDye800. Tumor uptake and detection of the antibody-dye conjugates compared with the IgG-IRDye800 control is shown in mice with SCC13 tumors using the SPY and Pearl systems. The conjugated antibodies produced TBRs of 1.2–2 using SPY and 1.6–3.6 using Pearl; in comparison, isotype control antibody IgG-IRDye produced TBRs of 1.0 (SPY) and 0.98 (Pearl). However, comparison between antibodies revealed them to be roughly equivalent for imaging purposes with both the SPY and Pearl (p = 0.89 SPY, p = 0.99 Pearl; one way ANOVA)

Tumor detection limit. Hypopharyngeal FaDu-luc2 tumors of different sizes visualized using bioluminescence imaged by a the IVIS Spectrum system could clearly be delineated in vivo using both b the Artemis and c Pearl. f In vivo tumor signal-to-background ratios (SBR) were calculated. Twenty-four hours after injection of 7D12-800CW and R2-800CW, all tumors were repeatedly halved until submillimeter size. Tumor pieces were measured using the d Artemis and e Pearl. g Contrast-to-noise ratios (CNR) were plotted against the volume of the tumor pieces. Ruler lines denote millimeters. K = kidney; T = tumor; M = muscle; A = Artemis; P = Pearl.

Figure 3. The antibody-dye conjugates were evaluated in human tumor explants. Imaging with the SPY and Pearl in mice with human cSCC tumor explants shows good tumor uptake and detection (A). Panitumumab-IRDye800 produced a higher TBR with the SPY and Pearl (B).

Tumor cells with eosinophilic cytoplasm forming a pearl. Note the distinct cytoplasmic borders (H&E 400×).